The Eplontersen Pregnancy and Lactation Outcomes Study
← catalyst calendarNCT07205666 · readout in 3,420 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With ICON plc.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
10estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-30 | actual | When the study began enrolling |
| Primary completion | 2035-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2035-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloidosis
Primary outcome
what the primary-completion date above is the date OFMajor congenital malformations
measured November 2025 - December 2035
Publications
- PMID 32169556 — reports results
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed